A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Condition:   Triple-Negative Breast Cancer Intervention:   Drug: camrelizumab in combination with nab-paclitaxel and famitinib Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials